# UCB Biopharma SRL clinical trials: 130 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 130 trials with UCB Biopharma SRL as lead sponsor, 14 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by UCB Biopharma SRL: 130 rows for $6.50, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/ucb-biopharma-srl

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 130
- Recruiting or not yet: 14
- Read on: November 19, 2026

## Trials

The 25 newest of 130, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07934472 | A Study to Evaluate the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic... | UCB Biopharma SRL | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934472) |
| September 30, 2026 | NCT07849894 | A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UCB0159 in Participants With Mild to Moderate Psoriasis, Single... | UCB Biopharma SRL | Phase 1 | Completed | Mild to Moderate Psoriasis, Healthy Volunteers | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07849894) |
| July 24, 2026 | NCT07725939 | A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic... | UCB Biopharma SRL | Phase 2 | Recruiting | Chronic Obstructive Pulmonary Disease With Chronic Bronchitis | 402 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07725939) |
| July 22, 2026 | NCT07720375 | A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis... | UCB Biopharma SRL | Phase 2 | Recruiting | Non-cystic Fibrosis Bronchiectasis | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07720375) |
| April 15, 2026 | NCT07531511 | SLC6A1-NDD Prospective Longitudinal Natural History Study | UCB Biopharma SRL | Observational | Recruiting | SLC6A1 Neurodevelopmental Disorder (NDD), Developmental and Epileptic Encephalopathies (DEE) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07531511) |
| March 11, 2026 | NCT07465289 | A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis | UCB Biopharma SRL | Phase 3 | Recruiting | Ocular Myasthenia Gravis | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07465289) |
| March 11, 2026 | NCT07463521 | A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis | UCB Biopharma SRL | Phase 3 | Recruiting | Ocular Myasthenia Gravis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07463521) |
| December 17, 2025 | NCT07290036 | A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults | UCB Biopharma SRL | Phase 1 | Recruiting | Psoriatic Arthritis, Axial Spondyloarthritis | 392 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07290036) |
| December 16, 2025 | NCT07286682 | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants | UCB Biopharma SRL | Phase 1 | Active not recruiting | Healthy Participants | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07286682) |
| December 11, 2025 | NCT07277660 | A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants... | UCB Biopharma SRL | Phase 2 | Active not recruiting | Atopic Dermatitis | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07277660) |
| November 24, 2025 | NCT07246564 | Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis | UCB Biopharma SRL | Phase 4 | Active not recruiting | Myasthenia Gravis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07246564) |
| October 24, 2025 | NCT07220551 | A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants | UCB Biopharma SRL | Phase 1 | Completed | Healthy Volunteers | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07220551) |
| October 21, 2025 | NCT07219420 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis | UCB Biopharma SRL | Phase 3 | Recruiting | Palmoplantar Pustulosis | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07219420) |
| June 13, 2025 | NCT07020988 | A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants | UCB Biopharma SRL | Phase 1 | Completed | Healthy Participants | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020988) |
| May 14, 2025 | NCT06970301 | A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants | UCB Biopharma SRL | Phase 1 | Completed | Healthy Study Participants | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06970301) |
| May 8, 2025 | NCT06961747 | A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women | UCB Biopharma SRL | Phase 1 | Recruiting | Healthy Participants | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06961747) |
| April 10, 2025 | NCT06921850 | A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis... | UCB Biopharma SRL | Phase 3 | Active not recruiting | Hidradenitis Suppurativa | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06921850) |
| March 21, 2025 | NCT06888193 | A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) | UCB Biopharma SRL | Phase 1 | Recruiting | Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06888193) |
| December 6, 2024 | NCT06720714 | A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women | UCB Biopharma SRL | Phase 1 | Completed | Healthy Participants | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06720714) |
| December 4, 2024 | NCT06716879 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants | UCB Biopharma SRL | Phase 1 | Completed | Healthy Participants | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06716879) |
| October 31, 2024 | NCT06668181 | An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile... | UCB Biopharma SRL | Phase 3 | Recruiting | Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06668181) |
| October 2, 2024 | NCT06624228 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis | UCB Biopharma SRL | Phase 3 | Completed | Psoriatic Arthritis | 553 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06624228) |
| September 27, 2024 | NCT06617325 | A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus... | UCB Biopharma SRL | Phase 3 | Recruiting | Systemic Lupus Erythematosus | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06617325) |
| August 15, 2024 | NCT06555601 | A First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB3101 in Healthy Participants | UCB Biopharma SRL | Phase 1 | Terminated | Healthy Participants | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06555601) |
| August 6, 2024 | NCT06540144 | An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis | UCB Biopharma SRL | Phase 3 | Active not recruiting | Generalized Myasthenia Gravis | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06540144) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 36 |
| Phase 1/2 | 4 |
| Phase 2 | 22 |
| Phase 2/3 | 2 |
| Phase 3 | 58 |
| Phase 4 | 2 |
| Not applicable | 4 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 79 |
| Terminated | 17 |
| Recruiting | 13 |
| Active not recruiting | 11 |
| No longer available | 4 |
| Enrolling by invitation | 3 |
| Withdrawn | 2 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Myasthenia Gravis | 14 |
| Psoriasis | 13 |
| Epilepsy | 13 |
| Arthritis, Psoriatic | 12 |
| Axial Spondyloarthritis | 7 |
| Hidradenitis Suppurativa | 6 |
| Parkinson Disease | 5 |
| Lupus Erythematosus, Systemic | 4 |
| Spondylitis, Ankylosing | 4 |
| Epilepsy, Absence | 3 |
| Dermatitis, Atopic | 3 |
| Arthritis, Rheumatoid | 3 |
| Crohn Disease | 3 |
| Purpura, Thrombocytopenic, Idiopathic | 3 |
| Arthritis | 2 |
| Non-Radiographic Axial Spondyloarthritis | 2 |
| Drug Resistant Epilepsy | 2 |
| Seizures | 2 |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 2 |
| Supranuclear Palsy, Progressive | 2 |
| Restless Legs Syndrome | 2 |
| Epilepsies, Partial | 1 |
| Pulmonary Disease, Chronic Obstructive | 1 |
| Bronchitis, Chronic | 1 |
| Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Business schools in the United States](https://specstream.ai/data/businesses/business-schools/united-states)
- [Bathtub and sink repair companies in the United States](https://specstream.ai/data/businesses/bathtub-and-sink-repair-companies/united-states)
- [B2B equipment maintenance and repair companies in the United States](https://specstream.ai/data/businesses/b2b-equipment-maintenance-and-repair-companies/united-states)
- [Anesthesiology practices in the United States](https://specstream.ai/data/businesses/anesthesiology-practices/united-states)
- [Whiskey bars in the United States](https://specstream.ai/data/businesses/whiskey-bars/united-states)
- [Turkish restaurants in the United States](https://specstream.ai/data/businesses/turkish-restaurants/united-states)
